About Swedish Orphan Biovitrum

Company Description

At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care.

- Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care
- Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets
- A strong portfolio of on-market products, and an extensive portfolio of pre-market assets
- An international biopharmaceutical company covering the entire value chain
- We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation

Year founded

2010

Served area

Worldwide

Headcount

1,509

Headquarters

Tomtebodavägen 23A, 17165 Solna – Sweden

Shareholder information

Shares outstanding

295,319,743

IPO

Sept. 15, 2006

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.